Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Renal Cancer - Targeted therapies rapidly take hold of market

Renal Cancer - Targeted therapies rapidly take hold of market

"IntroductionIn the 7 major markets, Datamonitor estimates that the incidence of RCC in 2007 will total 86,800 cases. Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%. This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC.ScopeAnalysis of RCC market based on a survey of 180 renal cancer specialists, supported by interviews carried out with key opinion leaders Segmentation of renal cancer patient population by disease subtype, disease stage at presentation and proportion receiving surgery and/or drug therapy In-depth analysis of treatment patterns in RCC by line of therapy, including most commonly prescribed drug regimens in 7 major markets Ranking of key prescribing influences in RCC, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overviewHighlightsPfizer's Sutent (sunitinib) is established as the standard-of-care for the first-line treatment of Stage IV RCC in most of the 7 major pharmaceutical markets. Bayer/Onyx's Nexavar (sorafenib) is the most commonly prescribed therapy in the second-line for Sutent-refractory patients. Wyeth's Torisel (temsirolimus) will soon be used in some poor-prognosis patients in the first-line and Genentech/Roche's Avastin (bevacizumab) may capture some of Sutent's first-line market share. Both drugs are also likely to compete for a share of the second-line market in Sutent-refractory patients. Due to high levels of unmet need in renal cancer, there is considerable activity in the late-phase renal cancer pipeline, with 9 drugs in Phase III development including 4 immunotherapies and 5 targeted therapies. The most promising drugs are Novartis's Certican (everolimus) and GlaxoSmithKline's pazopanib.Reasons to PurchaseIdentify key prescribing factors that influence prescription patterns for systemic therapy in renal cancer Examine the significant unmet need within renal cancer and identify opportunities for new product development Enhance commercial positioning by increasing understanding of current dynamics within the renal cancer market"

15-Oct-07 Format: PDF & SlidePack Pages: 193
Table of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions